incidence of Klebsiella pneumoniae clinical isolates to
drugs in intensive care units.
Shehabi AA, Mahafzah A, Baadran I, Qadar FA, Dajani N.
Microbiol Infect Dis. 2000 Jan;36(1):53-6.
Department of Pathology-Microbiology, Faculty of Medicine,
Jordan University Hospital, Amman.
A prospective study conducted among Jordanian ICU patients in
1997 using Etest identified resistance rates among isolates of
E. coli (25%-44%), Enterobacter spp. (54%-62%), and Klebsiella
spp. (30%-80%) to extended-spectrum B-lactams (ESBLs):
ceftazidime, cefotaxime, ceftriaxone, and aztreonam. All these
isolates were susceptible to imipenem and showed low resistance
rate to ciprofloxacin (5%-19%) and amikacin (13%-18%). Higher
and significant resistance rates of Klebsiella isolates to
ceftazidime (80%) and aztreonam (65%) were observed in 1997
compared with a previous study performed in 1994. The majority
of Klebsiella pneumoniae (70%) express different ESBL phenotypes
that were almost resistant to aztreonam and ceftazidime but
susceptible or resistant to cefotaxime and/or ceftriaxone. This
prospective study strongly suggests that ESBL production of
Klebsiella pneumoniae isolates have been highly disseminated
among ICU patients during 1997.
PMID: 10744368 [PubMed - indexed for MEDLINE]